Rubicon Research
Market cap ₹27,451 Cr
- P/E
- 85.04
- Day range
- ₹1,640.00 – ₹1,697.00
- 52-week range
- ₹609.25 – ₹1,899.00
- Volume
- 61,438
- Open
- ₹1,683.90
- Prev close
- ₹1,683.90
Latest results · Q2 FY27(consolidated)Revenue ₹576 Cr+39.9%Profit ₹90 Cr+67.9%Margin 15.7%YoY vs the same quarter last year
3 red flags to read up on
- high
Promoters selling in the market
Promoter group sold a net ₹2325 Cr on the open market in 90 days · 26 Aug 2026
- high
Under Additional surveillance (ASM)
The exchange has put this stock under Additional surveillance (ASM), Stage I · 18 Nov 2026
- medium
Promoter holding falling
51.25%, down 8.74 pts since 2025-10-15 · 30 Sept 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
RUBICON in NSE indices and F&O
Research profile
Composite 60 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.2%
- Graham no.
- ₹193.62
- vs Graham
- -88.3%
- ROE ÷ P/B
- 1.4%
- 12-1 mom.
- +143.2%
- Return / vol
- 3.81
- Magic Formula
- #373
- Piotroski
- 5/6
- FCF yield
- -0.1%
- PEG
- 1.25
Appears in 12 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Rubicon ResearchRUBICON | ₹27,451 Cr | 85.04 | 19.54 | 27.0% | 28.0% | 25.0% | 0.35 | +39.8% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 52m agoHeadlines about Rubicon Research from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 85.2
- Price / Book
- 19.37
- ROE (FY26)
- 27.0%
- ROCE (latest year)
- 28%
- Dividend yield
- 0.09%
Moving averages (NSE)
- 20-day
- ₹1,622.48
- Price above
- 50-day
- ₹1,643.66
- Price above
- 200-day
- ₹1,263.8
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- Public
- DII
- FII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Financial statements
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 296 | 313 | 358 | 352 | 412 | 476 | 514 | 534 | 576 |
| Expenses | 234 | 244 | 286 | 273 | 318 | 367 | 395 | 405 | 432 |
| Operating Profit | 62 | 70 | 72 | 79 | 94 | 108 | 119 | 129 | 144 |
| OPM % | 21% | 22% | 20% | 22% | 23% | 23% | 23% | 24% | 25% |
| Other Income | 3 | 0 | 0 | 1 | 1 | 4 | 3 | 6 | 2 |
| Interest | 7 | 8 | 12 | 11 | 11 | 10 | 10 | 9 | 11 |
| Depreciation | 8 | 9 | 10 | 10 | 12 | 12 | 12 | 15 | 18 |
| Profit before tax | 49 | 53 | 51 | 60 | 72 | 91 | 99 | 110 | 117 |
| Tax % | 30% | 28% | 29% | 27% | 25% | 20% | 22% | 23% | 23% |
| Net Profit | 34 | 38 | 36 | 43 | 54 | 73 | 77 | 85 | 90 |
| EPS in Rs | ₹2.23 | ₹2.47 | ₹2.35 | ₹2.80 | ₹3.49 | ₹4.42 | ₹4.65 | ₹5.13 | ₹5.47 |
From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
-52 days since Mar 2021
+42 days since Mar 2021
+14 days since Mar 2021
-24 days since Mar 2021
-45 days since Mar 2021
Strengths, risks & growth
Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, & commercialization of differentiated formulations. [1]
Strengths
- Company is expected to give good quarter
- Company has delivered good profit growth of 52.0% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 27.5%
Risks
- Stock is trading at 19.6 times its book value
- Promoter holding has decreased over last quarter: -8.51%
- Working capital days have increased from 68.8 days to 104 days
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- +41%
- 3 Years
- +65%
- TTM
- +46%
Compounded Profit Growth
- 10 Years
- —
- 5 Years
- +52%
- 3 Years
- +155%
- TTM
- +89%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- 1 Year
- +125%
Return on Equity
- 10 Years
- —
- 5 Years
- +16%
- 3 Years
- +27%
- Last Year
- +27%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 59.99% | 59.86% | 59.76% | 51.25% | -8.51 pp |
| FII | 7.99% | 7.54% | 7.52% | 9.01% | +1.49 pp |
| DII | 9.45% | 10.02% | 9.43% | 15.73% | +6.30 pp |
| Public | 22.57% | 22.57% | 23.29% | 24.03% | +0.74 pp |
Filed with NSE for Sept 2026: promoters 51.25%, public 48.75%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 13.78% (+6.55 pp)- Promoters51.3%
- Foreign institutions9.0%
- Mutual funds13.8%
- Insurance0.2%
- Other domestic institutions1.8%
- Retail3.3%
- Others20.7%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Kotak Mid Cap Fund | 2.18% | 0.94% | +0.13 pp |
| Motilal Oswal Small Cap Fund | 1.27% | 4.27% | -0.15 pp |
| HDFC Balanced Advantage Fund | 1.04% | 0.28% | +0.28 pp |
| SBI Multicap Fund | 1.00% | 1.22% | +1.22 pp |
| Kotak Large & Mid Cap Fund | 0.96% | 0.87% | +0.87 pp |
Scorecard
- Performance
- Avg
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Avg
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 268 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 43.9%
- Downside volatility
- 34.5%
- Worst 5% of days
- 3.3%
- Average of that tail
- 4.5%
- Max drawdown (1Y)
- 23.4%
- Below its peak
- 10.9%
Against the market
- Beta vs Nifty 50
- 0.34
- Correlation
- 0.11
- Relative strength (3M)
- -11.7%
- ATR (14)
- 4.1%
Return
- Return 1M
- +9.9%
- Return 3M
- -7.8%
- Return 6M
- +66.3%
- Return 1Y
- +167.4%
- vs 200-day average
- +31.2%
Momentum
- RSI (14)
- 51.8
- MACD histogram
- 4.23
- Stochastic %K
- 50.2
- ADX (14)
- 19.0
- +DI / −DI
- 16.6 / 21.0
- Money flow index
- 59.5
Participation
- Delivery (20d avg)
- 51.2%
- vs its 60-day baseline
- +0.0 pts
- Volume vs 20-day
- -1.0σ
- Close vs day's VWAP
- -0.2%
- 52-week position
- 84 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
5 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — passed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — failed
- Free cash flow
- -₹24 Cr
- FCF yield
- -0.1%
- Cash conversion
- 0.83
- Accruals ratio
- 0.018
- Net debt
- ₹292 Cr
- Net debt / equity
- 0.21
- EV / sales
- 13.21
- PEG
- 1.25
- Capex intensity
- 16.4%
- Revenue CAGR
- 39.9%
- Profit CAGR
- 67.9%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
GIRISH SUBRAMANIAM IYER Employee · Market Sale | Sell | 1,000 | ₹18.1 L | 15 Sept 2026 |
GIRISH SUBRAMANIAM IYER Employee · Market Sale | Sell | 1,500 | ₹27.3 L | 15 Sept 2026 |
GIRISH SUBRAMANIAM IYER Employee · Market Sale | Sell | 1,296 | ₹23.2 L | 15 Sept 2026 |
GIRISH SUBRAMANIAM IYER Employee · Market Sale | Sell | 3,000 | ₹54.9 L | 15 Sept 2026 |
Vinayak Sawant Employee · Market Sale | Sell | 1,100 | ₹20.3 L | 4 Sept 2026 |
Vinayak Sawant Employee · Market Sale | Sell | 1,100 | ₹20.3 L | 4 Sept 2026 |
Vinayak Sawant Employee · Market Sale | Sell | 1,100 | ₹20.3 L | 4 Sept 2026 |
Vinayak Sawant Employee · Market Sale | Sell | 1,100 | ₹20.3 L | 4 Sept 2026 |
Vinayak Sawant Employee · Market Sale | Sell | 1,100 | ₹20.3 L | 4 Sept 2026 |
Vinayak Sawant Employee · Market Sale | Sell | 1,100 | ₹20.3 L | 4 Sept 2026 |
General Atlantic Singapore RR Pte Ltd Promoter · Market Sale | Sell | 1,46,927 | ₹25.4 Cr | 28 Aug 2026 |
General Atlantic Singapore RR Pte Ltd Promoter · Market Sale | Sell | 1,38,53,073 | ₹2300 Cr | 28 Aug 2026 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Corporate actions
- dividend₹1.50
Dividend - Rs 1.50 Per Share
7 Aug 2026ex-date
Company announcements
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - US FDA inspection of the Company's manufacturing facility in Satara, Maharashtra, India
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Intimation under Regulation 30 of the SEBI (Listing Obligations and Dislcosure Requirements) Regulatoins 2015, (SEBI Listing Regulations) ESOP alottment
Intimation of Trading Window Closure
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for General Atlantic Singapore RR Pte Ltd
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for General Atlantic Singapore RR Pte Ltd
Voting Results along with the Scrutinizers Report of the 27th Annual General Meeting of the Company, held on Wednesday, 26th August 2026.
Summary of the Proceedings of the 27th Annual General Meeting of the Company.
Trascript of Earnings Call Q1 FY 2026-27
Newspaper Publication
Audio Recording of earnings conference call for the quarter ended 30th June, 2026
Monitoring Agency Report for the Quarter ended June 30, 2026.
Disclosure under Regulation 30 (SEBI LODR) Outcome of Board Meeting
Investor Presentation
Unaudited Financials Results for Quarter ended June 30, 2026
Filed with BSE (scrip 544578); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Aug 2026TranscriptSlidesRecording
- Jun 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlidesRecording
- Nov 2025TranscriptSlides
Credit ratings
- Rating update · 16 Jul 2025 from fitch
- Rating update · 17 Apr 2024 from fitch
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 5 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Rubicon Research: common questions
Answered from the figures on this page.